Yang Xueli, Zhang Zhengquan, Jia Xiaoqing, Zhang Yanqin, Mu Tianyang, Zhou Bingzheng, Li Lin, Fu Deyuan, Hu Xin, Xiong Shunbin
Department of Cancer Stem Cell, Dalian Medical University, Dalian 116000, China.
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200030, China.
J Thorac Dis. 2017 Apr;9(4):1002-1011. doi: 10.21037/jtd.2017.03.108.
PLA2G16 functions as a phosphatase in metabolism and its abnormal expression is closely associated with tumor progression. The aim of this study is to investigate the prognosis value of PLA2G16 in breast cancer.
A tissue microarray including 200 invasive ductal carcinoma specimens was constructed. Immunohistochemistry was performed to determine the PLA2G16 expression status. The Kaplan-Meier analysis and log-rank test were used to evaluate the prognostic value of PLA2G16. The Multivariate Cox regression analysis was performed to identify whether PLA2G16 was an independent prognostic factor.
In our retrospective study, Kaplan-Meier analysis showed that elevated PLA2G16 expression was correlated with improved DFS (P=0.032) in the whole breast cancer patients. In further subgroup analysis, PLA2G16 overexpression was found to be associated with prolonged DFS (P=0.018) in HER2-positive breast cancer patients. More importantly, Multivariate analysis suggested that PLA2G16 was a significant independent prognostic factor in HER2-enriched patients [hazard ratio (HR) =0.151; 95% confidence interval (CI) =0.034-0.672; P=0.013].
Our study evaluated the prognostic significance of PLA2G16 in patients with HER2-positive breast cancer and confirmed the relevance of this metabolism-related gene in patient outcome.
PLA2G16在代谢过程中发挥磷酸酶的作用，其异常表达与肿瘤进展密切相关。本研究旨在探讨PLA2G16在乳腺癌中的预后价值。
构建包含200例浸润性导管癌标本的组织芯片。采用免疫组织化学法检测PLA2G16的表达情况。运用Kaplan-Meier分析和对数秩检验评估PLA2G16的预后价值。进行多因素Cox回归分析以确定PLA2G16是否为独立预后因素。
在我们的回顾性研究中，Kaplan-Meier分析显示，在整个乳腺癌患者中，PLA2G16表达升高与无病生存期（DFS）改善相关（P=0.032）。在进一步的亚组分析中，发现PLA2G16过表达与HER2阳性乳腺癌患者的DFS延长相关（P=0.018）。更重要的是，多因素分析表明，PLA2G16是HER2富集型患者的一个显著独立预后因素[风险比（HR）=0.151；95%置信区间（CI）=0.034-0.672；P=0.013]。
我们的研究评估了PLA2G16在HER2阳性乳腺癌患者中的预后意义，并证实了这个与代谢相关的基因与患者预后的相关性。
